Table 1 PODXL expression and clinicopathological parameters of the cohort

n (%)

73 (100)

55 (75,3)

18 (24,7)

p-value

Age

≤75

49 (67,1)

36 (65,5)

13 (72,2)

0.77

>75

24 (32,9)

19 (34,5)

5 (27,8)

Gender

Female

36 (49,3)

20 (36,4)

16 (88,9)

<0,001

Male

37 (50,7)

35 (63,6)

2 (11,1)

T

1

2 (2,7)

1 (1,8)

1 (5,6)

0.62

2

13 (17,8)

11 (20,0)

2 (11,1)

3

46 (63,0)

35 (63,6)

11 (61,1)

4

12 (16,4)

8 (14,5)

4 (22,2)

N

0

40 (54,8)

34 (61,8)

6 (33,3)

0.09

1

21 (28,8)

14 (25,5)

7 (38,9)

2

12 (16,4)

7 (12,7)

5 (27,8)

M

0

69 (94,5)

52 (94,5)

17 (94,4)

0.99

1

4 (5,5)

3 (5,5)

1 (5,6)

Stage

I

11 (15,1)

9 (16,4)

2 (11,1)

0.24

II

28 (38,4)

24 (43,6)

4 (22,2)

III

30 (41,1)

19 (34,5)

11 (61,1)

IV

4 (5,5)

3 (5,5)

1 (5,6)

Diff grade

Intermed-high

58 (79,4)

48 (87,3)

10 (55,6)

0.02

Low

14 (19,2)

7 (12,7)

7 (38,9)

Missing

1 (1,4)

1 (5,6)

Mucinous histology

Absent

63 (86,3)

51 (92,7)

12 (66,7)

0.01

Present

10 (13,7)

4 (7,3)

6 (33,3)

Vascular invasion

Absent

57 (78,1)

45 (81,8)

12 (66,7)

0.2

Present

16 (21,9)

10 (18,2)

6 (33,3)

Neural invasion

Absent

67 (91,8)

52 (94,5)

15 (83,3)

0.16

Present

6 (8,2)

3 (5,5)

3 (16,7)

Location

Colon

40 (54,8)

28 (50,9)

12 (66,7)

0.29

Rectum

33 (45,2)

27 (49,1)

6 (33,3)

Neoadj radiation (n=33)1

25 Gy

18 (54,5)

14 (51,8)

4 (66,7)

0.91

50,4 Gy + cap

3 (9,1)

2 (7,4)

1 (16,7)

No

12 (36,4)

11 (40,7)

1 (16,7)

Adj treatment

Yes

19 (26,0)

8 (14,5)

11 (61,1)

<0,001

No

54 (74,0)

47 (85,5)

7 (38,9)